Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Raw Materials (2016 - 2018)

Sanofi's Raw Materials history spans 4 years, with the latest figure at $1.2 billion for Q4 2018.

  • On a quarterly basis, Raw Materials rose 2.38% to $1.2 billion in Q4 2018 year-over-year; TTM through Dec 2018 was $1.2 billion, a 2.38% increase, with the full-year FY2018 number at $1.2 billion, up 2.38% from a year prior.
  • Raw Materials hit $1.2 billion in Q4 2018 for Sanofi, up from $1.1 billion in the prior quarter.
  • Over the last five years, Raw Materials for SNY hit a ceiling of $1.2 billion in Q4 2018 and a floor of $1.0 billion in Q4 2016.
  • Historically, Raw Materials has averaged $1.1 billion across 4 years, with a median of $1.1 billion in 2015.
  • Biggest five-year swings in Raw Materials: fell 2.62% in 2016 and later grew 10.54% in 2017.
  • Tracing SNY's Raw Materials over 4 years: stood at $1.1 billion in 2015, then dropped by 2.62% to $1.0 billion in 2016, then grew by 10.54% to $1.1 billion in 2017, then rose by 2.38% to $1.2 billion in 2018.
  • Business Quant data shows Raw Materials for SNY at $1.2 billion in Q4 2018, $1.1 billion in Q4 2017, and $1.0 billion in Q4 2016.